BioCryst Pharmaceuticals BCRX Available-for-Sale Debt Securities - Amortized Cost
Available-for-Sale Debt Securities - Amortized Cost at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's available-for-sale debt securities - amortized cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's available-for-sale debt securities - amortized cost?
- BioCryst Pharmaceuticals (BCRX) reported available-for-sale debt securities - amortized cost of $86.7M in Q1 2026.
- How has BioCryst Pharmaceuticals's available-for-sale debt securities - amortized cost changed year-over-year?
- BioCryst Pharmaceuticals's available-for-sale debt securities - amortized cost decreased by 58.6% year-over-year, from $209.2M to $86.7M.
- What is the long-term trend for BioCryst Pharmaceuticals's available-for-sale debt securities - amortized cost?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's available-for-sale debt securities - amortized cost has grown at a 20.9% compound annual growth rate (CAGR), from $138.2M to $244.46M.
- What does available-for-sale debt securities - amortized cost mean?
- This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.